Key Highlights
● Second-quarter revenue from continuing operations rose 28.9 per cent to $570.3 million.
● Adjusted operating margin fell to 19.6 per cent from 24.8 per cent a year earlier.
● The company completed the sale of its OEM business for $1.5 billion in cash.
● Full-year adjusted diluted earnings per share guidance was raised to $6.90 to $7.20.
Teleflex Incorporated (NYSE:TFX), which trades on the New York Stock Exchange as TFX, is a global medical technology provider based in Wayne, Pennsylvania. It describes its focus areas as anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access and urology, with brands including Arrow, LMA, QuikClot, UroLift and Weck. The company has been reshaping its portfolio, so the figures below relate to continuing operations. Chief executive Jason Weidman lists operational rigour, innovation-led platforms and disciplined capital deployment as priorities, and says they should support a meaningfully stronger financial profile in 2027 and beyond.
Second-Quarter 2026 Results
Second-quarter 2026 results, reported on 6 August 2026, show a business in transition. Revenue from continuing operations was $570.3 million, up 28.9 per cent as reported but 4.7 per cent on a pro forma adjusted constant-currency basis, the difference reflecting the Biotronik Vascular Intervention acquisition. GAAP diluted earnings per share were $0.96 against $1.54 a year earlier, while adjusted earnings per share were $1.76 against $1.73. Adjusted operating margin was 19.6 per cent, down from 24.8 per cent, and adjusted gross margin was 61.7 per cent against 64.5 per cent. By segment, Vascular revenue was $246.3 million, Interventional $211.9 million and Surgical $112.1 million; pro forma constant-currency growth was 8.0 per cent, a decline of 1.0 per cent and 9.2 per cent respectively. Six-month revenue was $1,118.6 million, with adjusted earnings per share of $3.14 against $3.17. Net income for the quarter was $99.7 million, including $57.9 million from discontinued operations.
Guidance, Divestitures and Integration
Management has raised or lowered several targets. Full-year 2026 guidance is for GAAP revenue of $2,260 million to $2,280 million, pro forma adjusted constant-currency growth of 3.5 to 4.5 per cent, and adjusted diluted earnings per share of $6.90 to $7.20, which the company described as an increase. GAAP earnings per share guidance of $2.54 to $2.84 was reduced. The company said integration of Biotronik Vascular Intervention is taking longer than expected, which led it to lower its revenue outlook. These are management expectations and may not be met. Teleflex has completed the sale of its OEM business for $1.5 billion in cash, with after-tax proceeds estimated at about $1.25 billion, and classifies the pending Acute Care and Interventional Urology divestitures as discontinued operations. The guidance excludes the accelerated repurchase and any potential tariff refunds. Cash and restricted cash equivalents were $316.9 million at 30 June 2026.
A Company Being Reshaped by Deals on Both Sides
Teleflex's headline revenue growth reflects its Biotronik Vascular Intervention acquisition rather than organic demand, since pro forma constant-currency growth was just 4.7 per cent, and management says integration is taking longer than expected, which led it to lower the revenue component of its outlook even as adjusted earnings guidance rose. With the OEM business sale completed for $1.5 billion and Acute Care and Interventional Urology divestitures still pending, the company is being reshaped from multiple directions at once, so the eventual post-separation portfolio, not any single quarter's results, is the central question for investors.



_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)

Please wait processing your request...